Ambrx Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ambrx Biopharma Inc (AMAM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ambrx Biopharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 9M vs 245,823M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-97.5% annualized vs trailing 12 months), vs decelerating (-46.4%) for its tracked peer group.
- Growth: Ambrx Biopharma Inc generated -96.7% revenue growth year over year in Q3 2023, vs 3.2% for its competitors combined.
- Profitability: Its -43,375.5% net margin compares with -1.4% for the peer group.
- Peer revenue share: Ambrx Biopharma Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.21M compares with $1.21M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AMAM Sales vs. its Competitors, Q3 2023
Ambrx Biopharma Inc reported revenue contraction of 96.68 % year on year in Q3 2023, below its competitors' combined revenue growth of 3.16 %.
With a net margin of -43,375.47 %, Ambrx Biopharma Inc reported lower profitability than its competitors (-1.39 %).
Ambrx Biopharma Inc generated 0.00 % of the combined sales of its peer group, down from 0.01 % a year earlier.
Ambrx Biopharma Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Ambrx Biopharma Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Ambrx Biopharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Ambrx Biopharma Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (126) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Ambrx Biopharma Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs -96.7% for Ambrx Biopharma Inc. Ambrx Biopharma Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Ambrx Biopharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ambrx Biopharma Inc | No | No | No | Yes |
| Competitors combined (68) | ||||
| High-Confidence Competitors (133) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 7) | 87.50 % (7 of 8) | 50.00 % (4 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AMAM Stock Performance relative to its Competitors
AMAM Stock Performance relative to High-Confidence Competitors
AMAM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Revolution Medicines Inc | 282.9% | Outperformed |
| 4 | Immunitybio inc | 282.9% | Outperformed |
| 5 | Checkpoint Therapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Ambrx Biopharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Ambrx Biopharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Ambrx Biopharma Inc |
1,743.01 | 8.60 |
 Eli Lilly And Company |
1,151,353.71 | 79,665.80 |
 Novartis Ag |
305,136.40 | 56,674.00 |
 Amgen Inc |
245,795.52 | 38,095.00 |
 Gilead Sciences Inc |
197,885.60 | 30,457.00 |
 Regeneron Pharmaceuticals Inc |
86,206.62 | 15,534.70 |
| SUBTOTAL | 2,306,148.79 | 245,895.74 |
Sign in to see all competitors of Ambrx Biopharma Inc .
Sources: Ambrx Biopharma Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Ambrx Biopharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Ambrx Biopharma Inc's Competitors Named by the Company
Competitive relationships identified from Ambrx Biopharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medtronic plc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Intuitive Surgical Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Globus Medical Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Acutus Medical Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Cardiovascular Systems, Inc. | Company report | 85% |
| Inspiremd Inc | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Biodexa Pharmaceuticals Plc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Addex Therapeutics Ltd | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Apexigen Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Compass Pathways Plc | Company report | 85% |
| Nexgel Inc | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Alpha Pro Tech Ltd | Company report | 85% |
| Pulse Biosciences Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Bone Biologics Corporation | Company report | 85% |
| Abivax Sa | Company report | 85% |
| The Cooper Companies Inc | Company report | 85% |
| Spyglass Pharma Inc | Company report | 85% |
| Lenz Therapeutics Inc | Company report | 85% |
| Starco Brands Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Xtant Medical Holdings Inc | Company report | 85% |
| Arrivent Biopharma inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Nanobiotix S a | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Sintx Technologies Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Ss Innovations International Inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Gh Research Plc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| INVO | Company report | 85% |
| Evolus Inc | Company report | 85% |
| Medinotec Inc | Company report | 85% |
| BSGM | Company report | 85% |
| NAYA | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Alkermes | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Otsuka Pharmaceutical | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Xoma Royalty Corporation | Company report | 85% |
| MNMD | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Philips N.V. | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| ENTO | Company report | 85% |
| Mira Pharmaceuticals Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
| Prestige Consumer Healthcare Inc | Company report | 85% |
| The Hain Celestial Group Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Glucotrack Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| The Honest Company Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Assembly Biosciences Inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Staar Surgical Co | Company report | 85% |
| Inmune Bio Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Allergan | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Aytu Biopharma Inc | Company report | 85% |
| Sunovion | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Alphatec Holdings Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Lyra Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Zevra Therapeutics Inc | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Relmada Therapeutics Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Cvrx inc | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Meihua International Medical Technologies Co Ltd | Company report | 85% |
| Surmodics Inc | Company report | 85% |
| Artivion Inc | Company report | 85% |
| Transmedics Group Inc | Company report | 85% |
| Silk Road Medical Inc | Company report | 85% |
| Axogen inc | Company report | 85% |
| Penumbra Inc | Company report | 85% |
| Procter and Gamble Co | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Semler Scientific inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Irhythm Holdings Inc | Company report | 85% |
| Si bone inc | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Non Invasive Monitoring Systems Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Smith and Nephew Plc | Company report | 85% |
| Bausch and Lomb Corp | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Conmed Corporation | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Surgalign Holdings Inc | Company report | 85% |
| Pacira Biosciences inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Establishment Labs Holdings Inc | Company report | 85% |
| Nuvasive Inc | Company report | 85% |
| Unilever Plc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
| Orchestra Biomed Holdings Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Minerva Neurosciences Inc | Company report | 85% |
| Organon and Co | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Est e Lauder Companies Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Vicarious Surgical Inc | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| 3m Company | Company report | 85% |
| Aptinyx Inc | Company report | 85% |
| Zimvie Inc | Company report | 85% |
| Insulet Corporation | Company report | 85% |
| Stereotaxis Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Inspire Medical Systems inc | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Colgate palmolive Company | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Asensus Surgical Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Alcon inc | Company report | 85% |
| Zimmer Biomet Holdings Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Journey Medical Corp | Company report | 85% |
| Karuna Therapeutics Inc | Company report | 85% |
| Cervomed Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Conformis inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Ambrx Biopharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Ambrx Biopharma Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Ambrx Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Ambrx Biopharma Inc .
Ambrx Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Ambrx Biopharma Inc | 1,743 | 209,805 | -3,271,049 |
| Eli Lilly And Company | 1,151,354 | 1,593,316 | 534,224 |
| Novartis Ag | 305,136 | 752,973 | 185,566 |
| Amgen Inc | 245,796 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 197,886 | 1,791,588 | -190,588 |
| Regeneron Pharmaceuticals Inc | 86,207 | 1,008,092 | 280,902 |
| PEERS TOTAL | 2,304,406 | 1,206,110 | 193,770 |
Sign in to see all peers for Ambrx Biopharma Inc .
Ambrx Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Gilead Sciences Inc | United States 70.78 % |
| Exelixis Inc | United States 91.44 % |
| Immunitybio inc | United States 98.99 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Ambrx Biopharma Inc .
Ambrx Biopharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (150 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 30.27 % (avg) | +69.7 pp |
| Operating Margin | -1,595.32 % | industry median | -1,357.9 pp |
| EBITDA Margin | -1,500.62 % | -6.00 % (avg) | -1,494.6 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 9.55 % (avg) | -9.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Ambrx Biopharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (150 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 23.4x | - |
| EV / EBITDA | - | 18.6x | - |
| P/B | 3.8x | 5.1x | -1.2x |
| Return on Equity | -67.63 % | industry aggregate | -70.74 % |
| Return on Invested Capital | -33.44 % | -12.01 % (avg) | -21.43 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Ambrx Biopharma Inc's Strategic Group Map
Every company in Ambrx Biopharma Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Ambrx Biopharma Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Ambrx Biopharma Inc's trailing-12-month revenue growth of -28.1% and operating margin of -1,595.3% compares with an average of 14.6% growth and -347.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Ambrx Biopharma Inc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Ambrx Biopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 9.55 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Ambrx Biopharma Inc's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Ambrx Biopharma Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Ambrx Biopharma Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Ambrx Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 1,357.9 points below the industry median.
- Return on equity 70.7 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-97.5% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (48.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-46.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Ambrx Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Ambrx Biopharma Inc | 9.52 | 10.53 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
Sign in to see all peers for Ambrx Biopharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Ambrx Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Ambrx Biopharma Inc | Q3 2023 | -96.7 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| PEERS TOTAL | +16.2 % | -46.1 % |
Sign in to see all peers for Ambrx Biopharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Ambrx Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Ambrx Biopharma Inc | Q3 2023 | - | +186.5 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
Sign in to see all peers for Ambrx Biopharma Inc .
Ambrx Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Ambrx Biopharma Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
Sign in to see all peers for Ambrx Biopharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Ambrx Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Ambrx Biopharma Inc | - | 202.63 |
| Eli Lilly And Company | 43.25 | 14.45 |
| Novartis Ag | 21.82 | 5.38 |
| Amgen Inc | 28.06 | 6.45 |
| Gilead Sciences Inc | - | 6.50 |
| Regeneron Pharmaceuticals Inc | 20.14 | 5.55 |
| PEERS AVERAGE | 58.58 | 9.38 |
Sign in to see all peers for Ambrx Biopharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.